Posters highlight antigen-independent delivery, differentiated efficacy and broad payload versatility of ultra pH-sensitive ...

Data demonstrate a scalable approach to better understand tumor cell behavior and inform drug developmentDALLAS--(BUSINESS WIRE)--SingleCell Biotechnology, a biotechnology company developing ...

Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class ...

Ultrasensitive, structural variant-based ctDNA monitoring reliably tracks therapeutic response and predicts progression in metastatic breast cancer, and is a strong independent prognostic marker in ...

Data highlight biomarker-linked activity and in vivo efficacy of STX-6398, supporting small-molecule CKAP2 modulation as a ...

(PRs) among 38 response-evaluable non-small cell lung cancer (NSCLC) patients (ORR 26%), including three of seven squamous cell NSCLC patients (ORR 43%)Five confirmed PRs among 19 response-evaluable ...

Cantargia AB (Publ) (Nasdaq Stockholm:CANTA) today reported that the rationale and study design of the phase 1b/2 clinical trial investigating nadunolimab in combination with immune-checkpoint ...

The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ ...

Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts.Derived predominantly from turmeric (~98.5%), maintaining a composition ...

The Electronic Skin Market is emerging as one of the most transformative segments within advanced materials and wearable ...

The global Medical Tourism market is projected to witness a robust growth rate of 23% during the forecast period, driven by ...

Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented in a podium session at ...